

PATENT
USSN 09/432,503
015389-002616US; 018/210c

APPENDIX

Other patents and applications

Recombinant hTRT	U.S. Patent 6,475,789; U.S. Patent 6,261,836; U.S. Patent 6,617,110; U.S. Patent 6,808,880; U.S. Patent 6,921,664; U.S. Patent 6,927,285; U.S. Patent 7,005,262; USSN 09/843,676 (allowed); USSN 08/974,584; USSN 09/432,503; USSN 09/721,477; USSN 09/721,506; USSN 10/053,758; USSN 10/044,692; USSN 10/877,022; USSN 10/877,124; USSN 10/044,539; USSN 10/877,146; USSN 11/207,078 (all pending)
hTRT variants	U.S. Patent 6,337,200; USSN 09/990,080 (allowed)
TRT from single cell ciliates	U.S. Patent 6,093,809; U.S. Patent 6,166,178; U.S. Patent 6,309,867
Mouse TRT	U.S. Patent 6,767,719; USSN 10/862,698
Telomerase holoenzyme purified from cells having telomerase activity	U.S. Patent 5,968,506; U.S. Patent 6,261,556; U.S. Patent 6,517,834; U.S. Patent 6,545,133; U.S. Patent 6,787,133; USSN 10/811,033
Use of recombinant hTRT in vaccine formulations	U.S. Patent 6,440,735; USSN 10/208,243; USSN 10/602,441
hTRT promoter	U.S. Patent 6,610,839; U.S. Patent 6,777,203; USSN 10/325,810; USSN 10/674,836
hTRT antisense oligonucleotides	U.S. Patent 6,444,650; U.S. Patent 6,627,619; USSN 10/637,443